Summary results across all cancer sites for outcomes related to adherence to guidelines
| Cancer site (no of audits included in analyses/no included in review)† | GP conformity | Appropriateness of type of referral | Ability of the guidelines to identify correct referral | |||
|---|---|---|---|---|---|---|
| Conformity of 2WW referrals to guidelines‡ | Non-2WW referrals with symptoms in line with guidelines¶ | 2WW referrals that warranted urgent referral according to hospital clinician | Clinical symptoms (at 1st appointment) matching 2WW GP referral | 2WW referrals not in line with guidelines but deemed clinically appropriate | 2WW referrals in line with guidelines but deemed clinically inappropriate | |
| 2WW, 2 week wait. | ||||||
| *Some of the percentages reported are based on a very small number of patients, i.e. <10. | ||||||
| †The audits included in the analyses (and therefore reported in this table) only include those that reported minimal data on how eligible patients were identified or the data source and reported separate results for individual cancer sites. | ||||||
| ‡2WWR: audits that included 2WW referrals; cancer: audits that included patients diagnosed with cancer. | ||||||
| ¶Referrals: audits that included all referrals; cancer: audits that included patients diagnosed with cancer. | ||||||
| Brain and CNS (12/12) | 2WWR: 0–100% (8 audits)* | – | 23–100% (4 audits)* | – | – | 22% (1 audit) |
| Breast (59/72) | 2WWR: 65–99% (20 audits) | Cancer: 0% (1 audit)* | 18–96% (9 audits) | 78% (1 audit) | 15–45% (2 audits) | 5–17% (2 audits) |
| Children (9/9) | 2WWR: 91–100% (4 audits)* | – | 60–100% (4 audits)* | – | – | – |
| Lower GI (47/71) | 2WWR: 53–100% (26 audits)* | Cancer: 29% (1 audit)* | 52–74% (6 audits) | 33–87% (3 audits) | 9–19% (2 audits) | 0% (1 audit) |
| Upper GI (36/54) | 2WWR: 76–100% (14 audits)* | Cancer: 100% (1 audit)* | 67–96% (5 audits) | 59–98% (2 audits) | 5–36% (2 audits) | 2% (1 audit) |
| Gynaecological (36/45) | 2WWR: 42–100% (19 audits)* | Cancer: 75% (1 audit)* | 64–94% (6 audits) | 82% (1 audit) | 0–25% (2 audits)* | 11% (1 audit) |
| Haematological (21/26) | 2WWR: 0–100% (10 audits)* | – | 75–100% (5 audits)* | 100% (1 audit)* | – | 0–26% (2 audits)* |
| Head and neck (23/30) | 2WWR: 0–86% (12 audits)* | Referrals: 35% (1 audit) Cancer: 100% (1 audit)* | 36–76% (6 audits) | 85% (1 audit) | 40–43% (2 audits)* | 10% (1 audit) |
| Lung (33/43) | 2WWR: 78–100% (15 audits) | – | 87–97% (5 audits) | 95% (1 audit) | 0–5% (2 audits)* | 6% (1 audit) |
| Sarcomas (10/11) | 2WWR: 60–100% (6 audits)* | Cancer: 100% (1 audit)* | 67–100% (4 audits)* | – | – | – |
| Skin (43/59) | 2WWR: 9–97% (20 audits)* | – | 13–84% (6 audits) | – | 1–42% (2 audits) | 3% (1 audit) |
| Urological (34/43) | 2WWR: 50–100% (15 audits)* Cancer: 94% (1 audit) | Referrals: 94% (1 audit) Cancer: 48% (1 audit) | 78–91% (4 audits) | 86% (1 audit) | 17% (1 audit)* | – |